MCID: GST111
MIFTS: 18

Gastroenteropancreatic Neuroendocrine Neoplasm

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Gastroenteropancreatic Neuroendocrine Neoplasm

MalaCards integrated aliases for Gastroenteropancreatic Neuroendocrine Neoplasm:

Name: Gastroenteropancreatic Neuroendocrine Neoplasm 58
Gep-Nen 58

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Orphanet 58 ORPHA100092

Summaries for Gastroenteropancreatic Neuroendocrine Neoplasm

MalaCards based summary : Gastroenteropancreatic Neuroendocrine Neoplasm, also known as gep-nen, is related to neuroendocrine tumor and neuroendocrine carcinoma. An important gene associated with Gastroenteropancreatic Neuroendocrine Neoplasm is CHGA (Chromogranin A). The drug Pharmaceutical Solutions has been mentioned in the context of this disorder. Affiliated tissues include myeloid, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Gastroenteropancreatic Neuroendocrine Neoplasm

Diseases related to Gastroenteropancreatic Neuroendocrine Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor 10.6
2 neuroendocrine carcinoma 10.2
3 b-lymphoblastic leukemia/lymphoma 10.1
4 small intestine neuroendocrine neoplasm 10.1
5 carcinoid syndrome 10.1
6 neuroendocrine neoplasm of appendix 10.1
7 pituitary carcinoma 9.8 MGMT CHGA
8 pleomorphic xanthoastrocytoma 9.8 MGMT CHGA
9 lung benign neoplasm 9.8 MGMT CHGA
10 malignant astrocytoma 9.7 MGMT CHGA
11 breast adenocarcinoma 9.7 MGMT CHGA
12 pick disease of brain 9.6 INA CHGA
13 adenoma 9.6 MGMT CHGA

Graphical network of the top 20 diseases related to Gastroenteropancreatic Neuroendocrine Neoplasm:



Diseases related to Gastroenteropancreatic Neuroendocrine Neoplasm

Symptoms & Phenotypes for Gastroenteropancreatic Neuroendocrine Neoplasm

GenomeRNAi Phenotypes related to Gastroenteropancreatic Neuroendocrine Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 9.36 INA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.36 CHGA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 9.36 INA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 9.36 CHGA
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 9.36 CHGA INA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 9.36 INA
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-215 9.36 CHGA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.36 INA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.36 CHGA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 9.36 CHGA

Drugs & Therapeutics for Gastroenteropancreatic Neuroendocrine Neoplasm

Drugs for Gastroenteropancreatic Neuroendocrine Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pharmaceutical Solutions Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients Recruiting NCT03422029 Phase 2 177Lu-Dotatate PRRT
2 Identification of Biomarker Profiles for Individualized Prognostic Stratification and Therapy in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia (GEP-NEN) Unknown status NCT02838862

Search NIH Clinical Center for Gastroenteropancreatic Neuroendocrine Neoplasm

Genetic Tests for Gastroenteropancreatic Neuroendocrine Neoplasm

Anatomical Context for Gastroenteropancreatic Neuroendocrine Neoplasm

MalaCards organs/tissues related to Gastroenteropancreatic Neuroendocrine Neoplasm:

40
Myeloid

Publications for Gastroenteropancreatic Neuroendocrine Neoplasm

Articles related to Gastroenteropancreatic Neuroendocrine Neoplasm:

(show top 50) (show all 105)
# Title Authors PMID Year
1
Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms. 61
33010002 2021
2
Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. 61
32615560 2021
3
Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference? 61
32155627 2021
4
Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. 61
33189127 2020
5
An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. 61
33159857 2020
6
Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms. 61
32156252 2020
7
Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management. Belgian multidisciplinary expert discussion based on a modified Delphi method. 61
33321023 2020
8
A consensus developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations. 61
33002892 2020
9
Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. 61
33096620 2020
10
Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. 61
32917216 2020
11
A tool to predict survival in stage IV entero-pancreatic NEN. 61
32892316 2020
12
[Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research]. 61
32676723 2020
13
An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm. 61
32872039 2020
14
Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report. 61
32533349 2020
15
Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? 61
31720931 2020
16
NEN: Advancement in Diagnosis and Minimally Invasive Therapy. 61
31747704 2020
17
Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumours: An ENETS Centre of Excellence Experience. 61
32335553 2020
18
Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias. 61
32291468 2020
19
Correlation of World Health Organization 2010 classification for gastroenteropancreatic neuroendocrine neoplasms with the prognosis of ovarian neuroendocrine neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study. 61
32097950 2020
20
Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. 61
31605174 2020
21
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. 61
33315908 2020
22
Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. 61
31557757 2020
23
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms. 61
31924180 2020
24
The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms. 61
31442475 2019
25
The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs. 61
30796708 2019
26
Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years. 61
31802438 2019
27
Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. 61
31077609 2019
28
Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. 61
31454281 2019
29
Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis. 61
31328428 2019
30
The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia. 61
31471333 2019
31
Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. 61
31368038 2019
32
[Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)]. 61
30969346 2019
33
Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. 61
30991982 2019
34
BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma. 61
30144031 2019
35
Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin. 61
30867449 2019
36
Nutritional and vitamin status in patients with neuroendocrine neoplasms. 61
30886501 2019
37
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. 61
30540557 2019
38
Clinicopathologic Characteristics and Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasm in a Multi-Ethnic Asian Institution. 61
30399612 2019
39
Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance. 61
30673674 2019
40
Spatio-temporal image correlation (STIC) in evaluation of advanced neuroendocrine tumours. 61
30633319 2019
41
PDGFRα expression as a novel therapeutic marker in well-differentiated neuroendocrine tumors. 61
30346879 2019
42
Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). 61
30153658 2019
43
The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. 61
31091247 2019
44
LncNEN885 inhibits epithelial-mesenchymal transition by partially regulation of Wnt/β-catenin signalling in gastroenteropancreatic neuroendocrine neoplasms. 61
30033597 2018
45
Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent. 61
29470627 2018
46
Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms. 61
29970506 2018
47
Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. 61
29387927 2018
48
Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm. 61
29940892 2018
49
Associations between Single Nucleotide Polymorphisms in the Mitochondrial DNA D-Loop Region and Outcome of Gastroenteropancreatic Neuroendocrine Neoplasm. 61
29970437 2018
50
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). 61
29511910 2018

Variations for Gastroenteropancreatic Neuroendocrine Neoplasm

Expression for Gastroenteropancreatic Neuroendocrine Neoplasm

Search GEO for disease gene expression data for Gastroenteropancreatic Neuroendocrine Neoplasm.

Pathways for Gastroenteropancreatic Neuroendocrine Neoplasm

GO Terms for Gastroenteropancreatic Neuroendocrine Neoplasm

Sources for Gastroenteropancreatic Neuroendocrine Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....